SCHEMBL2901256

SCHEMBL2901256

COC(=O)c1cc(N=C=S)c(C(=O)OC)cc1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.37
FGFR1 P11362 1/20 0.37
PDGFRA P16234 1/20 0.37
FLT1 P17948 1/20 0.37
FGFR3 P22607 1/20 0.37
KDR P35968 1/20 0.37
KDM4E B2RXH2 6/20 0.36
GAA P10253 4/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
GLA P06280 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.34
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
CA12 O43570 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18029472 0.92 MAPT (0.36) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL10289261 0.86 KDM4E (0.41) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL2894967 0.83 KDM4E (0.46) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL2903057 0.83 ALDH1A1 (0.39) KDM4EMAPTALDH1A1HPGDHSD17B10
SCHEMBL2901109 0.83 GAA (0.42) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL15216074 0.81 KDM4E (0.51) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL2902887 0.80 KDM4E (0.33) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL11377571 0.80 GAA (0.43) FGFR1KDM4EGAAMAPTALDH1A1
SCHEMBL11377711 0.79 KDM4E (0.46) FGFR1KDM4EGAAMAPTALDH1A1
SCHEMBL2900923 0.79 KDM4E (0.53) KDM4EGAAMAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012058211-A2 QUINAZOLINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO EMORY UNIVERSITY (US) 2012-05-03 WO disclosed
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 PDGFRB 949/4885FGFR1 2336/4885PDGFRA 472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.